Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 7/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.51 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.48 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DTYMK | P23919 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26213504 | 1.00 | RNASEL (0.57) | RNASELP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL26212708 | 1.00 | RNASEL (0.57) | RNASELP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL26214912 | 0.98 | RNASEL (0.55) | RNASELP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL26627446 | 0.98 | RNASEL (0.55) | RNASELP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL26215118 | 0.97 | RNASEL (0.54) | RNASELP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL26214907 | 0.97 | RNASEL (0.54) | RNASELP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL26213523 | 0.97 | RNASEL (0.54) | RNASELP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL26202543 | 0.97 | RNASEL (0.55) | RNASELP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL26202547 | 0.97 | RNASEL (0.55) | RNASELP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL26572252 | 0.97 | RNASEL (0.55) | RNASELP2RY2P2RY4P2RY6P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023159930-A1 | COMPOUND FOR RNA CAPPING AND APPLICATION OF COMPOUND | 广州市恒诺康医药科技有限公司 | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | RNGTT, RNMT, NSUN2 | RNASEL 72/4885P2RY2 4360/4885P2RY4 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.